Oxford University

Covid Rules at University of Oxford to Remain Unchanged After July 19th

The number of settings in which life will continue as it is now after ‘Freedom Day’ keeps growing. Most recently, students at the University of Oxford have been told that rules on mask-wearing and social distancing will remain unchanged after July 19th due to high infection rates in the county.

The number of positive Covid tests in Oxford has been on the up in recent weeks, but deaths remain low, with zero deaths having been recorded in seven of the last 10 weeks and no more than three deaths recorded in the other three weeks.

Graph from Oxfordshire County Council.

University leaders haven’t let this stop them imposing tough lockdown restrictions. In an email sent to staff and students on Tuesday (and kindly forwarded to us at Lockdown Sceptics by a reader), Baroness Royall of Blaisdon, the Principal of Somerville College, said measures would remain “until further notice”.

Please note that, whilst the Government has confirmed plans to lift Covid restrictions on Monday, July 19th, the University’s policies on social distancing, face coverings and working from home will not change due to the high rates of Covid in Oxford. We will therefore continue with our Covid restrictions in College until further notice and, for the moment, we will not be allowing visitors.

On its website, the University warns that “Covid remains a real threat to many people in our community and… the pandemic is not yet over”. Students are instructed to continue following these measures:

  • Continue social distancing – assume two metres within University buildings unless told otherwise.
  • Keep washing your hands.
  • Keep wearing a face covering (unless you’re exempt).
  • Get tested – twice a week, with Lateral Flow Devices (LFDs); and take a PCR test if you have symptoms or have received a positive LFD test result or have been advised that you are a close contact of someone who has a PCR-confirmed case of Covid.
  • Continue to follow the self-isolation guidance.

If we can’t banish these restrictions from one of the country’s – the world’s – most learned institutions, what chance have we got of scrapping them from pubs and restaurants?

Ivermectin: Oxford University to Trial Promising, Easily Available Drug as Early Treatment for COVID-19

The Principle trial at the University of Oxford has selected Ivermectin for inclusion in its study of repurposed drugs for treatment of COVID-19. It will be given to people with Covid symptoms to see if it can keep them out of hospital. The BBC has the story.

The Principle study will compare those given the drug to patients receiving the usual NHS care.

The drug has become controversial after being promoted for use across Latin America and in South Africa, despite being so far unproven.

Previous studies of Ivermectin have generally been small or low quality.

Most commonly used to treat parasitic infections such as river blindness, spread by flies, Ivermectin has also been shown to kill viruses in petri dishes in the lab – although, at much higher doses than would usually be prescribed to people.

Ivermectin has been championed by many doctors and scientists since its apparent effectiveness as a Covid treatment emerged early in April 2020, but has been snubbed by mainstream health bodies for reasons that are unclear, leading some to suspect ulterior motives such as sustaining a vaccine narrative or prioritising newer and more profitable treatments. Merck, which manufactures Ivermectin but also recently signed a $356 million deal to supply the US with a much more expensive, experimental anti-Covid drug, went so far as to issue a statement casting doubt on the drug’s safety, even though its safety profile is well known and mild. Scientists trying to publish studies on the drug found the door being shut in their faces with apparent political motives for the refusal. Finally in May, the American Journal of Therapeutics published a peer-reviewed article by Dr Pierre Kory and colleagues entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19“. Dr Tess Lawrie and colleagues’ meta-analysis, finding a 62% reduction in risk of death among those infected or at high risk of Covid infection (on moderate-certainty evidence), was published in the same journal last week.

While, in a pandemic, the precautionary principle would seem to recommend authorising the use of safe, repurposed drugs that (small) trials have shown appear to work, health authorities apparently did not agree and said there must be higher quality evidence for Ivermectin before it can be approved. Yet because there is little profit in a cheap, out-of-patent drug these higher quality trials have not been done, leaving the drug still without approval or definitive evaluation over 14 months after its apparent efficacy against COVID-19 was discovered. If it does turn out to be as highly effective as the early studies suggest, this will mean the delay will have been responsible for failing to prevent many thousands of deaths around the world.

Still, better late than never, and credit to Oxford for including it in its study despite the politics around it. The Principle trial should provide the definitive answer as to whether Ivermectin is effective at preventing the progression to serious coronavirus disease when used at an early stage.

People aged 18-64 with an underlying health condition or experiencing breathlessness, and anyone aged 65 or over, can sign up to the Principle trial within 14 days of having Covid symptoms or receiving a positive test.

Official: Covid Pandemic Over in Britain

With the ONS reporting today that the number of people infected with COVID-19 in England has fallen to its lowest level since September, researchers at Oxford have said the vaccines are so effective that the UK is no longer in the midst of a pandemic. Sarah Knapton, Science Editor of the Telegraph, has more.

In the first large real-world study of the impact of vaccination on the general population, researchers found that the rollout is having a major impact on cutting both symptomatic and asymptomatic cases.

Sarah Walker, Professor of Medical Statistics and Epidemiology at Oxford and Chief Investigator on the Office for National Statistics COVID-19 Infection Survey, said that Britain had “moved from a pandemic to an endemic situation” where the virus is circulating at a low, largely controllable level in the community.

The new research, based on throat swabs from 373,402 people between December 1st last year and April 3rd, found three weeks after one dose of either the Pfizer or AstraZeneca jab, symptomatic infections fell by 74% and infections without symptoms by 57%.

By two doses, asymptomatic infections were down 70% and symptomatic by 90%.

It comes as infections continue to fall in Britain, dropping 7% in a week, despite the reopening of schools and shops. Deaths have also fallen by 26% and admissions by 19% over the last seven days.

New data from the ONS also showed that Covid was no longer the leading cause of death in March, falling behind dementia and heart disease, for the first time since October.

Worth reading in full.

Stop Press: Just 6% of beds are now taken up by Covid patients at England’s busiest NHS Trust compared to 60% at peak of second wave, an analysis of NHS data by MailOnline shows.